IMR Press / RCM / Volume 24 / Issue 12 / DOI: 10.31083/j.rcm2412346
Open Access Original Research
Feasibility of a Percutaneous and Non-Fluoroscopic Procedure for Transcatheter Mitral Valve Edge-to-Edge Repair
Show Less
1 Department of Structural Heart Disease, National Center for Cardiovascular Disease, China & State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 100037 Beijing, China
2 National Health Commission Key Laboratory of Cardiovascular Regeneration Medicine, National Clinical Research Center for Cardiovascular Diseases, 100037 Beijing, China
3 Department of Anesthesiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 100037 Beijing, China
4 Department of Pediatric Cardiac Surgery, Huazhong Fuwai Hospital, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, 451464 Zhengzhou, Henan, China
*Correspondence: panxiangbin@fuwaihospital.org (Xiangbin Pan)
These authors contributed equally.
Rev. Cardiovasc. Med. 2023, 24(12), 346; https://doi.org/10.31083/j.rcm2412346
Submitted: 20 March 2023 | Revised: 11 July 2023 | Accepted: 17 July 2023 | Published: 12 December 2023
(This article belongs to the Section Cardiovascular Intervention and Therapeutics)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Background: Transcatheter edge-to-edge repair (TEER) of the mitral valve has emerged as an alternative treatment for mitral regurgitation (MR). However, the high radiation exposure during the process has been associated with multiple adverse effects for medical staff. In this study, we assessed the feasibility and safety of TEER performed solely under the echocardiographic (echo) guidance. Methods: Between April 2021 to August 2021, we retrospectively collected characteristics of 23 patients with MR who underwent TEER under echocardiographic guidance exclusively. Follow-up evaluations were performed at 1- , 3-months and 1-year post procedure. Results: All 23 patients (mean age, 66.1 ± 12.1 years; 65.2% males) successfully underwent echo-guided TEER, with 22 patients under transesophageal echo (TEE) guidance and 1 patient under transthoracic echo (TTE) guidance for severe esophageal stenosis. Of the patients, 60.9% received 1 implant and 39.1% received 2 implants. The median total procedural time was 130 (interquartile range, IQR: 90–150) min and the device procedure time was 73 (IQR: 58–100) min. The median length of stay was 6 (IQR: 5–9) days. At 3-months follow-up, 63.6% of patients had an MR 1+ and 90.9% had an MR 2+ (p < 0.001 vs. baseline). Improvement in functional status was observed, with 40.9% of patients classified as New York Heart Association (NYHA) functional class I and 45.5% as NYHA functional class II (p < 0.001 compared to baseline) at 3-months. At 1-year follow-up, 90.4% maintained MR reduction with MR 2+ (p < 0.001 vs. baseline). Single leaflet device attachment (SLDA) occurred in one patient (4.3%) 1-week post procedure. Conclusions: This retrospective, single-center, and pilot study demonstrates the feasibility, safety, and low complication rates of TEER guided solely by echocardiography. Our findings support the systematic use of echocardiography as the sole guidance modality for TEER, highlighting its potential as an alternative to fluoroscopy-guided procedures. Further multicenter and comparative studies are warranted to confirm these results and provide a more comprehensive evaluation of this approach.

Keywords
mitral regurgitation
transcatheter mitral valve repair
MitraClip
echocardiography
interventional therapy
Funding
2019PT350005/Fundamental Research Funds for the Central Universities
81970444/National Natural Science Foundation of China
Z201100005420030/Beijing Municipal Science and Technology Project
2020-RSW02/National high level talents special support plan
2021-I2M-1-065/CAMS Innovation Fund for Medical Sciences
Figures
Fig. 1.
Share
Back to top